surmount-1 trial tirzepatide non-diabetic weight loss (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants SURMOUNT 1 // Three-Year Obesty
Description
If you are considering Tirzepatide as part of your care plan, there are several important factors to keep in mind to ensure both safety and success
What if my compound tirzepatide looks cloudy
We ship to all Colombia
They can also experience fatigue and swelling in the legs, among other symptoms
Call or text us anytime (real humans, all U S.-based)
Reduced appetite on tirzepatide naturally reduces protein intake along with everything else
